Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $33.5M | $251K | $0.00 |
| Revenue growth | — | -99.3% | -100.0% |
| Operating income | -$30.7M | -$67.3M | -$89.8M |
| Operating margin | -91.6% | -26805.6% | — |
| Net income | -$28.7M | -$65.4M | -$83.9M |
| Net margin | -85.8% | -26045.0% | — |
| EPS (diluted) | -$35.78 | -$5.81 | -$3.43 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$47.4M | -$55.0M | -$76.8M |
| Capital expenditures | $3.26M | $642K | $2.59M |
| Free cash flow | -$50.7M | -$55.7M | -$79.3M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $53.5M | $40.2M | $26.7M |
| Total assets | $105M | $210M | $131M |
| Total liabilities | $50.7M | $22.9M | $21.0M |
| Shareholders' equity | -$162M | $187M | $110M |
| Retained earnings | -$181M | -$247M | -$331M |
| Shares (wtd avg diluted) | 803K | 11.3M | 24.4M |
Every figure is extracted from Artiva Biotherapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.